Department of Dermatology, Erasmus Medical Center, Rotterdam, the Netherlands.
Department of Research & Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands.
JAMA Dermatol. 2020 Dec 1;156(12):1300-1306. doi: 10.1001/jamadermatol.2020.3677.
Until now, most studies on cutaneous squamous cell carcinoma (cSCC) incidence rates concerned only the first cSCC per patient. Given the increase in incidence rates and the frequent occurrence of subsequent cSCCs per patient, population-based data on the incidence rates of both first and multiple cSCCs are needed.
To calculate annual age-standardized incidence rates for histopathologically confirmed first and multiple cSCCs per patient and to estimate future cSCC incidence rates up to 2027.
DESIGN, SETTING, AND PARTICIPANTS: A nationwide population-based epidemiologic cohort study used cancer registry data on 145 618 patients with a first histopathologically confirmed cSCC diagnosed between January 1, 1989, and December 31, 2017, from the Netherlands Cancer Registry and all patients with multiple cSCCs diagnosed in 2017.
Age-standardized incidence rates for cSCC-standardized to the European Standard Population 2013 and United States Standard Population 2000-were calculated per sex, age group, body site, and disease stage. A regression model with positive slope was fitted to estimate cSCC incidence rates up to 2027.
A total of 145 618 patients in the Dutch population (84 572 male patients [58.1%]; mean [SD] age, 74.5 [11.5] years) received a diagnosis of a first cSCC between 1989 and 2017. Based on incident data, European Standardized Rates (ESRs) increased substantially, with the highest increase found among female patients from 2002 to 2017, at 8.2% (95% CI, 7.6%-8.8%) per year. The ESRs for first cSCC per patient in 2017 were 107.6 per 100 000 person-years (PY) for male patients, an increase from 40.0 per 100 000 PY in 1989, and 68.7 per 100 000 PY for female patients, an increase from 13.9 per 100 000 PY in 1989, which corresponds with a US Standardized Rate of 71.4 per 100 000 PY in 2017 for men and 46.4 per 100 000 PY in 2017 for women. Considering multiple cSCCs per patient, ESRs increased by 58.4% for men (from 107.6 per 100 000 PY to 170.4 per 100 000 PY) and 34.8% for women (from 68.7 per 100 000 PY to 92.6 per 100 000 PY). Estimation of ESRs for the next decade show a further increase of 23.0% for male patients (ESR up to 132.4 per 100 000 PY [95% prediction interval, 125.8-139.0 per 100 000 PY]) and 29.4% for female patients (ESR up to 88.9 per 100 000 PY [95% prediction interval, 84.3-93.5 per 100 000 PY]).
This nationwide epidemiologic cohort study suggests that incidence rates of cSCC keep increasing, especially among female patients, and that the occurrence of multiple cSCCs per patient significantly adds to the current and future burden on dermatologic health care. Revision of skin cancer policies are needed to halt this increasing trend.
到目前为止,大多数关于皮肤鳞状细胞癌(cSCC)发病率的研究仅涉及每位患者的首次 cSCC。鉴于发病率的增加以及每位患者随后发生的 cSCC 的频繁发生,需要基于人群的数据来了解首次和多次 cSCC 的发病率。
计算每位患者首次和多次病理证实的 cSCC 的年龄标准化发病率,并估计到 2027 年的未来 cSCC 发病率。
设计、地点和参与者:一项全国性基于人群的流行病学队列研究使用了荷兰癌症登记处 1989 年 1 月 1 日至 2017 年 12 月 31 日期间诊断的 145618 例首次病理证实的 cSCC 患者以及 2017 年诊断的所有多次 cSCC 患者的癌症登记数据。
根据欧洲标准人口 2013 年和美国标准人口 2000 年进行标准化的 cSCC 年龄标准化发病率,按性别、年龄组、身体部位和疾病阶段进行计算。使用正斜率回归模型来估计到 2027 年的 cSCC 发病率。
荷兰人群中共有 145618 例患者(84572 例男性患者[58.1%];平均[标准差]年龄为 74.5[11.5]岁)在 1989 年至 2017 年期间诊断出首次 cSCC。根据发病数据,欧洲标准化发病率(ESR)大幅增加,其中女性患者从 2002 年到 2017 年的增长率最高,为每年 8.2%(95%置信区间,7.6%-8.8%)。2017 年每位患者首次 cSCC 的 ESR 为男性患者 107.6/100000 人年,比 1989 年的 40.0/100000 人年增加,女性患者为 68.7/100000 人年,比 1989 年的 13.9/100000 人年增加,这与 2017 年男性患者的美国标准化发病率 71.4/100000 人年和女性患者的 46.4/100000 人年相对应。考虑到每位患者的多次 cSCC,男性患者的 ESR 增加了 58.4%(从 107.6/100000 人年增加到 170.4/100000 人年),女性患者的 ESR 增加了 34.8%(从 68.7/100000 人年增加到 92.6/100000 人年)。对未来十年 ESR 的估计显示,男性患者的发病率进一步增加 23.0%(ESR 高达 132.4/100000 人年[95%预测区间,125.8-139.0/100000 人年]),女性患者的发病率增加 29.4%(ESR 高达 88.9/100000 人年[95%预测区间,84.3-93.5/100000 人年])。
这项全国性的基于人群的流行病学队列研究表明,cSCC 的发病率持续上升,尤其是在女性患者中,每位患者多次发生 cSCC 的情况显著增加了当前和未来皮肤保健的负担。需要修订皮肤癌政策以阻止这一上升趋势。